Caroline Elisabeth Nunes-Xavier

  • Principal investigator; PhD
  • +47 22 78 18 75

Dr. Nunes-Xavier is an experimental biologist and cancer researcher that initiated her career at the University of Oslo, where she obtained a Bachelor Degree in Natural Sciences (2005) and a Master Degree in Molecular Biology (2006). During the Master Degree, she made a mobility stay, within the Erasmus program, to the University of Valencia (Spain), where she obtained an additional Master Degree in Molecular Biology (2007). Afterwards she was awarded with a Marie Skłodowska-Curie Fellowship to perform her PhD (2007-2011), as part of a European Research Network training program, and obtained her European PhD at the University of Valencia (Spain) in 2011. During her PhD period she performed secondments at Karolinska Institute in Sweden and Weizmann Institute in Israel. Dr. Nunes-Xavier started as a postdoc at Oslo University Hospital in 2013 with a fellowship from the Norwegian Cancer Society. Since 2015 Dr. Nunes-Xavier has been a Principal Investigator and a holder of a FRIPRO mobility grant from The Research Council of Norway, co-funded by Marie Skłodowska-Curie Actions.

Dr. Nunes-Xavier main research line is to define novel targets in cancer treatment, with a focus on immune checkpoint proteins and protein tyrosine phosphatases. The pursued goals will have an important clinical translation to overcome or prevent cancer disease progression and current resistance to therapy.

 

Publications 2019

Calvete J, Larrinaga G, Errarte P, Martín AM, Dotor A, Esquinas C, Nunes-Xavier CE, Pulido R, López JI, Angulo JC (2019)
The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder
Hum Pathol, 91, 61-68
DOI 10.1016/j.humpath.2019.07.002, PubMed 31279874

Flem-Karlsen K, Fodstad Y, Nunes-Xavier CE (2019)
B7-H3 immune checkpoint protein in human cancer
Curr Med Chem (in press)
DOI 10.2174/0929867326666190517115515, PubMed 31099317

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Mingo J, Luna S, Gaafar A, Nunes-Xavier CE, Torices L, Mosteiro L, Ruiz R, Guerra I, Llarena R, Angulo JC, López JI, Pulido R (2019)
Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology
NPJ Precis Oncol, 3, 11
DOI 10.1038/s41698-019-0083-4, PubMed 30993208

Nunes-Xavier CE, Angulo JC, Pulido R, López JI (2019)
A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
Curr Urol Rep, 20 (1), 1
DOI 10.1007/s11934-019-0866-8, PubMed 30645700

Nunes-Xavier CE, Zaldumbide L, Aurtenetxe O, López-Almaraz R, López JI, Pulido R (2019)
Dual-Specificity Phosphatases in Neuroblastoma Cell Growth and Differentiation
Int J Mol Sci, 20 (5)
DOI 10.3390/ijms20051170, PubMed 30866462

Pulido R, Mingo J, Gaafar A, Nunes-Xavier CE, Luna S, Torices L, Angulo JC, López JI (2019)
Precise Immunodetection of PTEN Protein in Human Neoplasia
Cold Spring Harb Perspect Med, 9 (12)
DOI 10.1101/cshperspect.a036293, PubMed 31501265

Publications 2018

Aurtenetxe O, Zaldumbide L, Erramuzpe A, López R, López JI, Cortés JM, Pulido R, Nunes-Xavier CE (2018)
DUSP5 expression associates with poor prognosis in human neuroblastoma
Exp Mol Pathol, 105 (3), 272-278
DOI 10.1016/j.yexmp.2018.08.008, PubMed 30171833

Flem-Karlsen K, Fodstad Ø, Tan M, Nunes-Xavier CE (2018)
B7-H3 in Cancer - Beyond Immune Regulation
Trends Cancer, 4 (6), 401-404
DOI 10.1016/j.trecan.2018.03.010, PubMed 29860983

Nunes-Xavier CE, Mingo J, López JI, Pulido R (2018)
The role of protein tyrosine phosphatases in prostate cancer biology
Biochim Biophys Acta Mol Cell Res, 1866 (1), 102-113
DOI 10.1016/j.bbamcr.2018.06.016, PubMed 30401533

Publications 2017

Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad Ø, Nunes-Xavier CE (2017)
Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells
Pigment Cell Melanoma Res, 30 (5), 467-476
DOI 10.1111/pcmr.12599, PubMed 28513992

Publications 2016

Alonso A, Nunes-Xavier CE, Bayón Y, Pulido R (2016)
The Extended Family of Protein Tyrosine Phosphatases
Methods Mol Biol, 1447, 1-23
DOI 10.1007/978-1-4939-3746-2_1, PubMed 27514797

Errarte P, Guarch R, Pulido R, Blanco L, Nunes-Xavier CE, Beitia M, Gil J, Angulo JC, López JI, Larrinaga G (2016)
The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases
PLoS One, 11 (12), e0169105
DOI 10.1371/journal.pone.0169105, PubMed 28033421

Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad Ø (2016)
Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
Oncotarget, 7 (6), 6891-901
DOI 10.18632/oncotarget.6902, PubMed 26771843

Nunes-Xavier CE, Pulido R (2016)
Global RT-PCR and RT-qPCR Analysis of the mRNA Expression of the Human PTPome
Methods Mol Biol, 1447, 25-37
DOI 10.1007/978-1-4939-3746-2_2, PubMed 27514798

Publications 2014

Nygren MK, Tekle C, Ingebrigtsen VA, Mäkelä R, Krohn M, Aure MR, Nunes-Xavier CE, Perälä M, Tramm T, Alsner J, Overgaard J, Nesland JM, Borgen E, Børresen-Dale AL, Fodstad Ø, Sahlberg KK, Leivonen SK (2014)
Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c
Br J Cancer, 110 (8), 2072-80
DOI 10.1038/bjc.2014.113, PubMed 24577056

Ríos P, Nunes-Xavier CE, Tabernero L, Köhn M, Pulido R (2014)
Dual-specificity phosphatases as molecular targets for inhibition in human disease
Antioxid Redox Signal, 20 (14), 2251-73
DOI 10.1089/ars.2013.5709, PubMed 24206177

Publications 2013

Nunes-Xavier CE, Martín-Pérez J, Elson A, Pulido R (2013)
Protein tyrosine phosphatases as novel targets in breast cancer therapy
Biochim Biophys Acta, 1836 (2), 211-26
DOI 10.1016/j.bbcan.2013.06.001, PubMed 23756181

Publications 2012

Cejudo-Marín R, Tárrega C, Nunes-Xavier CE, Pulido R (2012)
Caspase-3 cleavage of DUSP6/MKP3 at the interdomain region generates active MKP3 fragments that regulate ERK1/2 subcellular localization and function
J Mol Biol, 420 (1-2), 128-38
DOI 10.1016/j.jmb.2012.04.004, PubMed 22504224

Publications 2011

Nunes-Xavier C, Romá-Mateo C, Ríos P, Tárrega C, Cejudo-Marín R, Tabernero L, Pulido R (2011)
Dual-specificity MAP kinase phosphatases as targets of cancer treatment
Anticancer Agents Med Chem, 11 (1), 109-32
DOI 10.2174/187152011794941190, PubMed 21288197

Nunes-Xavier CE, Elson A, Pulido R (2011)
Epidermal growth factor receptor (EGFR)-mediated positive feedback of protein-tyrosine phosphatase epsilon (PTPepsilon) on ERK1/2 and AKT protein pathways is required for survival of human breast cancer cells
J Biol Chem, 287 (5), 3433-44
DOI 10.1074/jbc.M111.293928, PubMed 22117074

Publications 2010

Nunes-Xavier CE, Tárrega C, Cejudo-Marín R, Frijhoff J, Sandin A, Ostman A, Pulido R (2010)
Differential up-regulation of MAP kinase phosphatases MKP3/DUSP6 and DUSP5 by Ets2 and c-Jun converge in the control of the growth arrest versus proliferation response of MCF-7 breast cancer cells to phorbol ester
J Biol Chem, 285 (34), 26417-30
DOI 10.1074/jbc.M110.121830, PubMed 20554528

Tárrega C, Nunes-Xavier C, Cejudo-Marín R, Martín-Pérez J, Pulido R (2010)
Studying the regulation of MAP Kinase by MAP Kinase phosphatases in vitro and in cell systems
Methods Mol Biol, 661, 305-21
DOI 10.1007/978-1-60761-795-2_18, PubMed 20811991

Page visits: 7280